Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab.
about
Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunityBiologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysisTocilizumab for rheumatoid arthritisComparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION studyTocilizumabAnimal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside-a Comprehensive ReviewMonoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitorsGene expression analysis in RA: towards personalized medicineBiologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritisEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updatePharmacokinetics, efficacy and safety profiles of etanercept monotherapy in Japanese patients with rheumatoid arthritis: review of seven clinical trialsBlocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statementDrug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis -- focus on subcutaneous tocilizumabAdalimumab for the treatment of rheumatoid arthritisComparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression AnalysisBiologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.Biologic therapies and bone loss in rheumatoid arthritis.Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry.Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor.Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radConcomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis.Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan.Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis.Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted BiologicsPower Doppler ultrasonography is useful for assessing disease activity and predicting joint destruction in rheumatoid arthritis patients receiving tocilizumab--preliminary data.Clinical efficacy of tocilizumab in patients with active rheumatoid arthritis in real clinical practice.Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy.Reduction of particle-induced osteolysis by interleukin-6 involves anti-inflammatory effect and inhibition of early osteoclast precursor differentiationBone damage in rheumatoid arthritis: mechanistic insights and approaches to preventionOverexpression of a minimal domain of calpastatin suppresses IL-6 production and Th17 development via reduced NF-κB and increased STAT5 signalsClinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies.Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study.Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsComparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial.New insights into T cell biology and T cell-directed therapy for autoimmunity, inflammation, and immunosuppressionInterleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy.Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of tPhase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis.
P2860
Q22306446-C2F6AE01-DA6A-4562-97F2-E5C2E342FD18Q24185797-600AEB50-D8FB-4AF5-B0A8-FA361B8CDACDQ24234126-EE653E60-6A96-4E16-9B78-1E42E65A4655Q24630541-1E0C8C36-EF1B-48E6-A27C-E98D68186AB0Q24655317-88198827-E81A-40C3-97C3-33E3F0CB1ACFQ26774874-0DD7C3FB-3D29-4604-BDB9-0A8CD8330C57Q26824970-FC0A4FFB-135E-4F6D-BB91-C2C00DA54569Q26825706-D6CFF94A-B964-4F6A-A92E-375E55D3D486Q26852235-050FBEAA-FBF7-4EA6-BAB5-063479C31049Q26859134-AEC1F0A7-C56B-4102-99BD-9984F70AA6C4Q27015772-6EF8F02C-A00E-4BD9-97D2-418FB253F1E9Q27021115-80F5810A-F2CA-4503-9705-084E72A6DE67Q27023091-1CE69617-3986-45F9-A70B-459F2C7B3DB3Q28282655-55DE5B82-CCCF-46D5-8782-15A46AEBB20EQ28547851-50A295A1-C2EF-47DE-AD28-34880706C76BQ30235341-81973B77-40B6-47B2-8A1E-FFD0D373EFCEQ30243911-DEAEDFA8-EC33-4FC8-89A2-C968ECDFF4E0Q30940329-B7D5BA3A-2554-403C-A023-F5FF4B855522Q33400381-38E3A686-E594-4629-9555-D4AEDD2CE37DQ33527462-AE8DC9F6-2898-45BF-AE39-FB0463BD6491Q33614786-5ABCEA7A-1578-43AA-B2B9-E382F920C5C2Q33725505-7F8ADB20-41AB-4B8B-AA26-1E642E5B103CQ33778719-63AD3AAB-DBA2-43DC-922F-F140A8756270Q33802181-5B818709-DEB3-4FF6-B85F-B5ADCAB8C1E2Q33809045-0C86FB01-B44E-4AFC-B1B6-7763C7DB20C8Q33811774-448E48BD-0062-4288-B97E-8BE3F382DDE1Q33880319-874EAD6B-8519-49FE-A5E5-77531240E6BCQ33921579-E27A4F11-2B49-4CFD-8537-A36EB33B081CQ33946711-C04825DD-CA0C-4E46-8675-1AAC664DA8C8Q34001621-5479A5B1-5E33-496F-AA83-7AB316CEBCE3Q34064908-4AA4119E-01C0-4C3B-A52A-B6D286E474F7Q34067792-538A7CDA-6DB2-45BF-8883-13DEA2C7A847Q34092425-8F2056B4-CA06-4085-A662-046C4331BA55Q34110049-A8B77954-A373-4B61-9652-CB511A179BBAQ34110066-E56434AF-E4E8-4C91-8FDA-448F36042E96Q34124686-5B3670AB-FC43-4ED6-A84C-7170569ACDA2Q34175958-306F984E-326C-4788-ABD4-9D7751A1CCBDQ34343286-C2F59385-1B24-4668-BCB3-38884E5578B0Q34394122-DE06FE0D-70D6-4510-8F6F-887B3B833B31Q34477442-061662AE-CF67-4734-ADFB-D3B142E82104
P2860
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Study of active controlled mon ...... ntrolled trial of tocilizumab.
@ast
Study of active controlled mon ...... ntrolled trial of tocilizumab.
@en
type
label
Study of active controlled mon ...... ntrolled trial of tocilizumab.
@ast
Study of active controlled mon ...... ntrolled trial of tocilizumab.
@en
prefLabel
Study of active controlled mon ...... ntrolled trial of tocilizumab.
@ast
Study of active controlled mon ...... ntrolled trial of tocilizumab.
@en
P2093
P2860
P356
P1476
Study of active controlled mon ...... ntrolled trial of tocilizumab.
@en
P2093
Jun Hashimoto
Kazuhiko Yamamoto
Nobuyuki Miyasaka
Norihiro Nishimoto
Norikazu Murata
Shinichi Kawai
Tadamitsu Kishimoto
Tsutomu Takeuchi
P2860
P304
P356
10.1136/ARD.2006.068064
P407
P577
2007-05-07T00:00:00Z